Kenvue Inc.

Kenvue Inc.

KVUE

$19.31

Updated: 04/11/2026, 14:37:17

Market Cap
$37.09B
Sector
Consumer Defensive
Industry
Household & Personal Products
Country
US

No historical data available

Company Profile

Kenvue Inc. functions as a global leader in the consumer health sector. The company structures its operations across three primary divisions: Self Care, Skin Health and Beauty, and Essential Health. Within the Self Care unit, it offers a diverse range of products for common conditions like coughs, colds, and allergies, in addition to pain relief, digestive health, and smoking cessation aids, featuring prominent brands such as Tylenol, Nicorette, and Zyrtec. The Skin Health and Beauty segment delivers various solutions for facial, body, hair, and sun protection, recognized under popular labels including Neutrogena, Aveeno, and OGX. Moreover, the Essential Health category provides oral hygiene, infant care, feminine wellness, and wound treatment products, marketed through esteemed brands like Listerine, Johnson's, Band-Aid, and Stayfree. Established in 2022, Kenvue Inc. maintains its corporate headquarters in Skillman, New Jersey, and operates as a subsidiary of Johnson & Johnson.

USD
NYSE
CEO: Kirk L. Perry
Employees: 21,890
https://www.kenvue.com
Asset Summaries
Latest generated summaries for KVUE

No summaries found.

Detailed business
Evidence-backed facts extracted from the latest official annual filing.
KVUE-10-k-fy2025.html3.3 MBtext/htmlENFiled 20/02/2026Period ended 28/12/2025

Business monitoring

Reported and calculated KPIs plus operational exposure disclosed in the FY 2025 filing.

Evidence-backed · 69 KPI observations

Revenue

$15.1B

FY 2025 · Reported

Net income

$1.5B

FY 2025 · Reported

Gross margin

58.1%

FY 2025 · Calculated

Free cash flow

$1.7B

FY 2025 · Calculated

R&D intensity

2.5%

FY 2025 · Calculated

Share repurchases

$0.2B

FY 2025 · Reported

Earnings and cash generation
USD billions, directly sourced from inline XBRL; free cash flow is operating cash flow less capex.
Profitability and reinvestment
Margins and R&D as a percentage of revenue.
Top products and services
Products and services mentioned in the filing; a quantitative sales breakdown was not disclosed.

Other offerings mentioned without separate sales

Essential Health segment product categories and brands
Self Care segment product categories and brands
Skin Health and Beauty segment product categories and brands
Connected health digital offerings

Area-level product sales are displayed only when the filing reports a product × geography breakdown. Regional totals are not allocated across products by estimation.

Geographic footprint
What the filing identifies, separated by location role so partner manufacturing is not presented as Apple-owned factories.
1 named headquarters
0 manufacturing countries
0 individually named factories

Map layer

Pins show disclosed operations. The heatmap colors the filing’s reported geographies; regional figures shade the region and are not estimates for each country.

No reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosure
Named headquarters Manufacturing partner country

Only locations and quantities explicitly supported by the filing are displayed. A country-level manufacturing percentage or product allocation is shown only when the source discloses it; materiality scores are never presented as production shares.

How the business makes money

World's largest pure-play consumer health company

World's largest pure-play consumer health company by revenue with $15.1 billion Net sales in FY2025; products marketed in more than 165 countries

99%
Source evidence
“we are the world’s largest pure-play consumer health company by revenue with $15.1 billion in Net sales in the fiscal year 2025”

Three reportable segments

Self Care; Skin Health and Beauty; Essential Health

99%
Source evidence
“Our portfolio includes Self Care, Skin Health and Beauty, and Essential Health products”

Reportable business segments

Self Care; Skin Health and Beauty; Essential Health

98%
Source evidence
“The following table summarizes the changes in the carrying amount of goodwill by reportable business segment”

Digital and e-commerce marketing model

Digital modern marketing company leveraging precision marketing, e-commerce, influencer and healthcare professional collaborations; uses media ROI analytics

95%
Source evidence
“we are a digital modern marketing company, and we collaborate with celebrities, influencers, and healthcare professionals to amplify brand awareness and product innovations”

Essential Health segment product categories and brands

Essential Health: Oral Care, Baby Care, Women's Health, Wound Care; brands include Listerine, BAND-AID Brand, Johnson’s, Stayfree, o.b.

99%
Source evidence
“Our Essential Health product categories include: Oral Care; Baby Care; and Other Essential Health (Women’s Health, Wound Care, and Other)”

Self Care segment product categories and brands

Self Care: Cough/Cold/Allergy, Pain Care, Digestive Health, Smoking Cessation, Eye Care; brands include Tylenol, Nicorette, Zyrtec, Benadryl, Motrin

99%
Source evidence
“Our Self Care product categories include: Cough, Cold, and Allergy; Pain Care; and Other Self Care (Digestive Health, Smoking Cessation, Eye Care, and Other)”

Skin Health and Beauty segment product categories and brands

Skin Health and Beauty: Face and Body Care; Hair, Sun, and Other; brands include Neutrogena, Aveeno, OGX, Dr.Ci:Labo, Rogaine

99%
Source evidence
“Our Skin Health and Beauty product categories include: Face and Body Care; and Hair, Sun, and Other”

Connected health digital offerings

Zyrtec® AllergyCast app and Neutrogena® Skin360 app connected health offerings

90%
Source evidence
“introduce innovative new products and connected health offerings, including the Zyrtec® AllergyCast app and the Neutrogena® Skin360 app”

Geographic markets served

Products connect with consumers across North America, APAC, EMEA, and LATAM; marketed in 165+ countries

95%
Source evidence
“allowing us to connect with consumers across North America, Asia Pacific (“APAC”), Europe, Middle East, and Africa (“EMEA”), and Latin America (“LATAM”)”

Operations and dependencies

Global manufacturing footprint

Global, balanced manufacturing footprint with digitally connected end-to-end supply chain; partnerships with key suppliers and retailers across multiple markets and channels

93%
Source evidence
“Our global and balanced manufacturing footprint provides us with the flexibility and agility to benefit from economies of scale and global supply chain agreements”

Relationship with J&J agreements

Separation Agreement and various agreements with J&J govern ongoing relationships; exiting TSA and Transition Manufacturing Agreement

95%
Source evidence
“including from exiting the Transition Services Agreement and the Transition Manufacturing Agreement with J&J”

Positioning and strategy

Science-backed brands endorsed by healthcare professionals

Iconic brand portfolio (Aveeno, BAND-AID, Listerine, Neutrogena, Tylenol, etc.) backed by science and recommended by healthcare professionals

95%
Source evidence
“our differentiated portfolio of iconic brands—including Aveeno®, BAND-AID® Brand, Johnson’s®, Listerine®, Neutrogena®, Nicorette®, Tylenol®, and Zyrtec®—is backed by science and recommended by healthcare professionals”

R&D organization scale

Global R&D team of ~1,600 scientists, doctors, pharmacists, and engineers; global network of innovation and development hubs

98%
Source evidence
“Our global team of approximately 1,600 scientists, doctors, pharmacists, and engineers has expertise across a range of core disciplines”

Our Vue Forward restructuring and post-separation transformation

Post-J&J separation transformation: exiting TSA/TMA with J&J, new operating model, Our Vue Forward cost savings to fuel brand investments

97%
Source evidence
“We have been focused on driving productivity and realizing cost savings from Our Vue Forward (as defined in Part II, Item 7)”

Digital strategy

Digital strategy spanning e-commerce, data analytics, AI/ML, and connected health offerings (Zyrtec AllergyCast, Neutrogena Skin360 apps)

95%
Source evidence
“we have pursued a new digital strategy across all aspects of our operations, and we intend to continue to accelerate our implementation of this strategy in the future.”

Risks, financing, and outlook

2023 Senior Notes issuance and J&J facility agreement

$7.75B senior unsecured notes issued March 22, 2023; net proceeds ~$7.7B loaned to J&J; J&J guarantees terminated

96%
Source evidence
“issued eight series of senior unsecured notes (the “2023 Senior Notes”) in an aggregate principal amount of $7.75 billion”

Skin Health and Beauty deteriorating outlook flagged

Slower skincare category growth and declining profitability drove revised forecasts; further deterioration could lead to goodwill impairment

95%
Source evidence
“The revised outlook aimed to address slower growth in the broader skincare categories, as well as the recent decline in profitability of the Skin Health and Beauty reporting unit.”

Separation from J&J timeline

IPO May 2023; J&J Exchange Offer completed August 2023; May 2024 Debt-for-Equity Exchange left J&J with no Kenvue shares

99%
Source evidence
“Following the completion of the Debt-for-Equity Exchange, J&J did not own any shares of our common stock.”

Proposed merger with Kimberly-Clark

Merger Agreement with Kimberly-Clark signed Nov 2, 2025; shareholders approved Jan 29, 2026; HSR waiting period expired Feb 4, 2026; still needs foreign regulatory approvals

99%
Source evidence
“On November 2, 2025, we entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Kimberly-Clark Corporation”

Proposed Transaction with Kimberly-Clark

Kenvue has a proposed merger transaction with Kimberly-Clark; shareholders will own K-C stock, with cash consideration financed partly by new K-C debt

98%
Source evidence
“the Proposed Transaction (as defined in Part I, Item 1, “Business—Company Overview—Proposed Transaction with Kimberly-Clark”)”

Skin Health and Beauty goodwill headroom thin; interim impairment test FY2025

Skin Health and Beauty reporting unit fair value exceeded carrying value by approximately 10%; +100bps discount rate would have triggered impairment

97%
Source evidence
“the estimated fair value of the Skin Health and Beauty reporting unit exceeded the carrying value by approximately 10%; therefore, no impairment charge was recorded”

Proposed transaction with K-C

Proposed Transaction with K-C pending, creating workforce and integration uncertainty

90%
Source evidence
“especially given the pendency and uncertainty created by the Proposed Transaction”

India regulatory change caused ORSL trade name impairment

$23M ORSL trade name impairment following regulatory changes in India

93%
Source evidence
“following regulatory changes in India”

Proposed Transaction completion risk

Failure or delay in consummating the Kimberly-Clark transaction could negatively impact business and stock price; fixed share ratio means shareholders cannot be sure of market value received

97%
Source evidence
“The number of shares of K-C common stock issuable in the First Merger in respect of one share of our common stock is fixed and will not be adjusted.”

Litigation exposure: acetaminophen, talc, phenylephrine

Concerns about acetaminophen, talc, and phenylephrine have resulted in litigation, regulatory action, and investigations, whether or not based on sound scientific evidence

96%
Source evidence
“Concerns about the reliability, safety, and efficacy of our products and their ingredients, including acetaminophen, talc, and phenylephrine, have resulted and could in the future result in litigation, regulatory action, governmental investigations, reputational damage, product recalls, product reformulations, or product withdrawals”

Failure to anticipate consumer preferences

Risk of lower sales/pricing pressure if market trends and consumer preferences are not anticipated

95%
Source evidence
“If we are unable to anticipate, understand, and respond appropriately to market trends and rapidly changing consumer and customer preferences, we may experience lower sales or increased pricing pressures, leading to excess inventory levels or lower gross margins”

Cybersecurity and Technology Systems risk

Cybersecurity breach risk across own and third-party Technology Systems; no material impact to date

95%
Source evidence
“To date, we have not experienced any material impact to our business or operations resulting from information security or cybersecurity incidents.”

J&J Separation-related liabilities and indemnities

Kenvue may incur indemnification obligations to J&J, including for potentially uncapped amounts; J&J's talc indemnity (US/Canada) may not fully protect Kenvue

95%
Source evidence
“J&J has agreed to indemnify us for certain liabilities, including the Talc-Related Liabilities (as defined below) for products sold in the United States and Canada, but such indemnity may not be sufficient to protect us against the full amount of such liabilities”

Private-label competition risk

Branded products risk losing share to private-label/generic products in uncertain economic conditions

95%
Source evidence
“we cannot predict with certainty the extent to which consumers will continue to favor our branded products over private-label and generic non-branded products, particularly during periods when economic conditions are uncertain.”

Restructuring execution risk

Restructuring initiative may not deliver expected cost savings/operational efficiencies

95%
Source evidence
“the recently announced restructuring initiative (as described in Note 20, "Subsequent Events," to the Consolidated Financial Statements included herein) that aims to optimize our operating model, transform our supply chain, reduce complexity, and drive operational efficiencies”

Inflation and raw material cost volatility

Inflationary pressures and raw material cost/availability volatility, including due to military conflicts, tariffs, and adverse economic conditions

94%
Source evidence
“Inflationary pressures and related volatility in the cost or availability of raw materials and other inputs for our products, including due to military conflicts, tariffs, and other adverse economic or market conditions.”

Third-party manufacturing and supply chain reliance

Reliance on third-party manufacturing and global supply chains reduces control and exposes to disruptions, shortages, and pricing of input materials

94%
Source evidence
“Our reliance on third parties in many aspects of our business, including to manufacture products, inherently involves a lesser degree of control over business operations, compliance matters, and cybersecurity.”

Information security / cybersecurity risk

Information security incidents and breaches of Kenvue or third-party technology systems could cause reputational damage, operational disruption, and significant costs

92%
Source evidence
“Information security incidents, including cybersecurity breaches, interruption, breakdown, corruption, destruction, breach, or failure of Technology Systems (as defined below) operated by us or a third party”

Legacy J&J branding transition

Continued use of legacy J&J branding, including the 'Johnson's®' brand; rebranding may fail to achieve market acceptance

90%
Source evidence
“Failure of our rebranding efforts in connection with the Separation to achieve market acceptance and the impact of our continued use of legacy J&J branding, including the “Johnson’s®” brand”

Trade policy / tariffs exposure

Exposure to new or increased tariffs, sanctions, quotas, or trade barriers

90%
Source evidence
“Potential changes in export/import and trade laws, regulations, and policies, such as new or increased tariffs, sanctions, quotas, or trade barriers”

Climate change and sustainability scrutiny

Climate change, extreme weather, natural disasters, and rapidly evolving sustainability requirements and stakeholder expectations

90%
Source evidence
“Climate change, extreme weather, and natural disasters, or legal, regulatory, or market measures to address climate change”

Artificial intelligence risk

Uncertainty in AI development, deployment, use, and regulation across operations, products, and services could adversely affect the company

90%
Source evidence
“Uncertainty in the development, deployment, use, and regulation of artificial intelligence in our internal processes, manufacturing operations, products, and services, as well as our business more broadly, could adversely affect us.”

Marketing effectiveness risk

Marketing/advertising cost inflation, agency consolidation, and FTC enforcement risk

90%
Source evidence
“if claims made by us or our third-party partners do not comply with the Endorsement Guides or any requirements of the FTC Act or similar state requirements, then the FTC and state authorities could subject us to investigations and enforcement actions”

Restructuring initiative and strategic review

Recently announced restructuring initiative and strategic review; expected benefits may not be realized or may take longer than expected

90%
Source evidence
“our recently announced restructuring initiative (as described in Note 20, “Subsequent Events,” to the Consolidated Financial Statements included herein)”

Global expansion risk

Global expansion may not yield positive returns for several years or at all

90%
Source evidence
“it is possible that positive returns on our investments in a market will not be achieved for several years, or at all.”

Artificial intelligence risk

Generative AI piloting with evolving regulatory/ethics risks; NIST AI RMF-based governance

90%
Source evidence
“We are piloting the use of systems and tools that incorporate artificial intelligence-based technologies, including generative artificial intelligence, in connection with supply chain and operations, content creation, as well as in various Kenvuer productivity enhancement use cases.”

Talent and workforce risk

Talent attraction/retention risk amid wage inflation, labor shortages, and union exposure

90%
Source evidence
“The market for highly skilled personnel and leaders in our industry is extremely competitive, and our ability to compete depends on our ability to hire, develop, motivate, and retain highly skilled personnel and leaders.”

Demand forecasting and inventory risk

Demand forecast errors may cause inventory write-downs or product shortages

90%
Source evidence
“Excess inventory levels may result in inventory write-downs or write-offs and the sale of excess inventory at discounted prices or in less preferred distribution channels”

Distribution channel expansion risk

Dependence on maintaining/expanding presence in existing and emerging distribution channels

85%
Source evidence
“maintain or expand our presence in existing and emerging distribution channels”

Privacy and data protection risk

Digital initiatives expose company to privacy/data protection and internet regulation risks

85%
Source evidence
“consumer privacy and data protection concerns, ethical concerns, changes in state tax regimes and government regulation of internet activities”

Material exposure graph

Skin Health and Beauty reporting unit
Competitive Exposure

Skin Health and Beauty goodwill ($2,263M) has only ~10% fair value headroom after revised outlook reflecting slower skincare category growth and declining profitability; +100bps discount rate would trigger impairment.

Relevance 95·Dependency 80·Confidence 95
Source evidence
“an increase of approximately 100 basis points in the selected discount rate would have resulted in an impairment charge”
Kimberly-Clark (K-C)
Revenue Exposure

The pending Proposed Transaction will convert Kenvue shareholders into K-C stockholders; completion depends on regulatory approvals and conditions, and K-C is expected to incur significant additional indebtedness to finance the Cash Consideration.

Relevance 95·Dependency 80·Confidence 97
Source evidence
“in connection with the Proposed Transaction, K-C is expected to incur significant additional indebtedness to finance the Cash Consideration”
Kimberly-Clark Corporation
Revenue Exposure

Pending merger with Kimberly-Clark will combine the company, subject to foreign regulatory approvals; major strategic event for investors.

Relevance 95·Dependency 60·Confidence 98
Source evidence
“The Merger Agreement provides for the combination of the Company and K-C upon the terms and subject to the conditions set forth therein”
Private-label and generic product consumers
Competitive Exposure

Consumer shifts toward private-label/generic alternatives, especially in uncertain economies, threaten KVUE branded product volume and pricing.

Relevance 85·Dependency 70·Confidence 90
Source evidence
“we cannot predict with certainty the extent to which consumers will continue to favor our branded products over private-label and generic non-branded products”
Self Care (OTC medicines)
Revenue Exposure

Self Care is one of three reportable segments; OTC medicines across cough/cold/allergy, pain care, digestive health, smoking cessation drive consumer health revenue.

Relevance 85·Dependency 70·Confidence 95
Source evidence
“Our Self Care brands offer accessibility to healthcare solutions with over-the-counter (“OTC”) medicines and other naturally inspired products.”
Consumer spending / economic conditions
Demand Driver

Economic uncertainty drives trade-down to private-label products, affecting KVUE sales volume and market share.

Relevance 80·Dependency 75·Confidence 85
Source evidence
“particularly during periods when economic conditions are uncertain”
Digital strategy and Technology Systems
Technology Dependency

Business increasingly depends on Technology Systems including cloud services; failures or breaches could disrupt operations, e-commerce, and manufacturing automation.

Relevance 80·Dependency 75·Confidence 90
Source evidence
“Our business is increasingly dependent on informational technology systems; operational technology systems; networks and services”
Johnson & Johnson
Supplier Dependency

Ongoing agreements with J&J (Separation Agreement, TSA, TMA) govern transition relationships; Kenvue is exiting the TSA and TMA while standing up its own systems.

Relevance 80·Dependency 55·Confidence 95
Source evidence
“exiting the Transition Services Agreement and the Transition Manufacturing Agreement with J&J”
private-label brands
Competitive Exposure

Private-label brands and generic non-branded products compete directly with Kenvue's products across all reportable segments and geographies, pressuring market share and pricing.

Relevance 75·Dependency 60·Confidence 94
Source evidence
“We face intense competition, including from multinational corporations, smaller regional companies, private-label brands, and generic non-branded products, in each of our reportable business segments and product lines”
E-commerce and digital marketing
Demand Driver

Precision marketing, e-commerce, and digital capabilities drive brand relevance, reach, and demand; media ROI analytics optimize spend.

Relevance 75·Dependency 50·Confidence 92
Source evidence
“leveraging our precision marketing, e-commerce, and broader digital capabilities to develop unique consumer insights”
key retailers
Customer Exposure

Kenvue depends on key retailers and their policies, plus e-commerce and alternative channels, in a rapidly changing retail landscape.

Relevance 70·Dependency 65·Confidence 92
Source evidence
“our dependence on key retailers, policies of our customers, e-commerce and other alternative retail channels”
consumer preferences and demand
Demand Driver

Kenvue's results depend on anticipating and responding to market trends, rapidly changing consumer and customer preferences, and shifting demand for its products.

Relevance 70·Dependency 65·Confidence 90
Source evidence
“Our ability to both innovate successfully and anticipate, understand, and respond appropriately to market trends, rapidly changing consumer and customer preferences, and shifting demand for our products.”
US (North America region)
Revenue Exposure

North America is one of four disclosed geographic regions through which the portfolio reaches consumers in 165+ countries.

Relevance 70·Dependency 60·Confidence 85
Source evidence
“allowing us to connect with consumers across North America, Asia Pacific (“APAC”), Europe, Middle East, and Africa (“EMEA”), and Latin America (“LATAM”)”
inflation
Cost Driver

Inflation and volatility in raw material and input costs, including due to military conflicts and tariffs, are explicit cost drivers for Kenvue's products.

Relevance 70·Dependency 60·Confidence 93
Source evidence
“Inflationary pressures and related volatility in the cost or availability of raw materials and other inputs for our products, including due to military conflicts, tariffs, and other adverse economic or market conditions.”
Johnson & Johnson (J&J)
Supplier Dependency

Kenvue relies on Transition Services and Transition Manufacturing Agreements with J&J, which may not be replaceable when they expire or terminate.

Relevance 70·Dependency 55·Confidence 93
Source evidence
“We may not be able to replace necessary manufacturing operations, systems, and services when the transition services agreement (the “Transition Services Agreement”) and the transition manufacturing agreement”
Healthcare professionals
Demand Driver

Brands recommended by healthcare professionals reinforce consumer connections and drive demand; HCPs engaged in R&D co-creation.

Relevance 70·Dependency 45·Confidence 93
Source evidence
“recommended by healthcare professionals, which further reinforces our consumers’ connections to our brands”
Privacy and data protection laws
Legal Exposure

Digital initiatives expose company to privacy law breaches and government regulation of internet activities.

Relevance 65·Dependency 60·Confidence 85
Source evidence
“A breach of privacy laws or unauthorized access, loss, or misuse of personal data could adversely affect us.”
tariffs and trade policy
Regulatory Exposure

Potential changes in trade laws, new or increased tariffs, sanctions, quotas, or trade barriers could affect Kenvue's global operations and costs.

Relevance 65·Dependency 55·Confidence 90
Source evidence
“Potential changes in export/import and trade laws, regulations, and policies, such as new or increased tariffs, sanctions, quotas, or trade barriers”
Johnson & Johnson (J&J)
Legal Exposure

J&J indemnifies Kenvue for Talc-Related Liabilities for products sold in the US and Canada, but the indemnity may be insufficient or J&J may not satisfy it.

Relevance 65·Dependency 50·Confidence 92
Source evidence
“J&J has agreed to indemnify us for certain liabilities, including the Talc-Related Liabilities (as defined below) for products sold in the United States and Canada, but such indemnity may not be sufficient”
Generative artificial intelligence
Technology Dependency

Piloting generative AI in supply chain, content creation, and productivity; presents governance, regulatory, and IP risks.

Relevance 65·Dependency 45·Confidence 85
Source evidence
“We are piloting the use of systems and tools that incorporate artificial intelligence-based technologies, including generative artificial intelligence”
Hart-Scott-Rodino Antitrust Improvements Act
Regulatory Exposure

Merger with Kimberly-Clark subject to antitrust clearance; HSR waiting period expired February 4, 2026, but foreign regulatory approvals remain pending.

Relevance 65·Dependency 40·Confidence 95
Source evidence
“the waiting period applicable to the Proposed Transaction under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, expired on February 4, 2026”
Skincare categories
Demand Driver

Slower growth in broader skincare categories drove the revised long-term outlook and interim impairment assessment for Skin Health and Beauty.

Relevance 60·Dependency 55·Confidence 90
Source evidence
“The revised outlook aimed to address slower growth in the broader skincare categories”
FTC Act and Endorsement Guides
Regulatory Exposure

Non-compliant advertising claims could trigger FTC investigations, penalties, and required marketing revisions.

Relevance 60·Dependency 55·Confidence 85
Source evidence
“then the FTC and state authorities could subject us to investigations and enforcement actions, impose penalties”
Wage inflation and labor market tightness
Cost Driver

Rising minimum wages and labor shortages increase hourly labor costs and complicate workforce changes.

Relevance 60·Dependency 55·Confidence 85
Source evidence
“Prevailing market wage rates for hourly employees have increased, and are expected to continue to increase, over time”
Johnson & Johnson
Legal Exposure

2023 Senior Notes proceeds were loaned to J&J via the April 5, 2023 Facility Agreement; J&J initially guaranteed the notes, with guarantees terminated upon the Consumer Health Business Transfer and Kenvue IPO.

Relevance 60·Dependency 40·Confidence 90
Source evidence
“Upon release from escrow, these funds were loaned to J&J through a facility agreement”
Interest rates
Cost Driver

Rising interest rates could reduce the excess of fair value over carrying value for reporting units and trigger goodwill impairment; $8.5B total debt and $700M commercial paper create rate exposure.

Relevance 55·Dependency 45·Confidence 88
Source evidence
“adverse macroeconomic developments such as rising interest rates, could significantly reduce the excess between fair value and carrying value”
Global conflicts
Geopolitical Exposure

Global conflicts increase cyberattack threats against company Technology Systems.

Relevance 55·Dependency 45·Confidence 80
Source evidence
“the global threat of cyberattacks has increased in response to global conflicts”
Digital diagnostics and telemedicine
Technology Dependency

Self Care brands deliver connected health offerings including digital diagnostics and telemedicine to expand personalized solutions.

Relevance 55·Dependency 35·Confidence 85
Source evidence
“These brands deliver connected health offerings, including digital diagnostics and telemedicine, to expand personalized solutions to consumers.”
Foreign currencies
Revenue Exposure

Goodwill and intangible gross carrying amounts moved materially with currency translation ($666M goodwill increase in FY2025 after a $428M decrease in FY2024), indicating significant non-USD exposure.

Relevance 50·Dependency 45·Confidence 85
Source evidence
“Currency translation508 78 80 666”
Full company information
Latest profile, trading, valuation, and identifier data stored for KVUE.
Share price
$19.31
Market cap
$37.09B
Exchange
NYSE
Currency
USD
CEO
Kirk L. Perry
Employees
21,890
IPO date
04/05/2023
Beta
0.447
Last dividend
$0.00
Day range
$19.20 – $20.00
52-week range
$15.94 – $20.13
1-day performance
-1.28%
1-year performance
21.14%
Current drawdown (1Y)
-4.07%
CIK
0001944048
CUSIP
49177J102
ISIN
US49177J1025
Created
07/12/2025, 05:00:28
Last update
04/11/2026, 14:37:17

Track Kenvue Inc. with an AI analyst

See which prediction-market events move KVUE, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Free forever to follow AlphaBrain’s AI strategies. No card required.